Treatment of Pityriasis Rubra Pilaris with Adalimumab: A Case Report

Main Article Content

Joshua R Kaminetsky
Eric J Feit
Jonathan P Ungar

Keywords

Abstract

Pityriasis Rubra Pilaris (PRP) is a rare inflammatory dermatosis of unknown etiology and variable presentation. Common clinical features include hyperkeratotic follicular papules, palmoplantar hyperkeratosis and well-demarcated red-orange scaly plaques interspersed with islands of unaffected skin. A limited body of anecdotal evidence predominantly supports the use of systemic retinoids and/or methotrexate in treating the disease. In a subset of these patients, there has been a documented role for biologic tumor necrosis factor (TNF) inhibitors, especially in patients who have failed retinoid or antimetabolite therapy. We present a case of a woman whose PRP responded favorably to adalimumab, highlighting the role of TNF inhibitors and the need for their continued exploration in the treatment of PRP.

References

Borok M, Lowe NJ. Pityriasis rubra pilaris. Further observations of systemic retinoid therapy. J Am Acad Dermatol. 1990;22(5 Pt 1):792.

Chapalain V, Beylot-Barry M, Doutre MS, Beylot C. Treatment of pityriasis rubra pilaris: a retrospective study of 14 patients. J Dermatolog Treat. 1999;10:113-117.

Zhang YH, Zhou Y, Ball N, Su MW, Xu JH, Zheng ZZ. Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy. J Cutan Med Surg. 2010 Jul;14(4):185-8.

Seckin D, Tula E, Ergun T. Successful use of etanercept in type I pityriasis rubra pilaris. Br J Dermatol 2008; 158: 642-4. 


Garcovich S, Di Giampetruzzi AR, Antonelli G, Garcovich A, Didona B. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol. 2010;24(8):881.

Walling HW, Swick BL. Pityriasis rubra pilaris responding rapidly to adalimumab. Arch Dermatol. 2009 Jan;145(1):99-101.1

O'Kane D, Devereux CE, Walsh MY, Hoey SE. Rapid and sustained remission of pityriasis rubra pilaris with adalimumab treatment. Clin Exp Dermatol. 2010;35(4):e155.

Schreml S, Zeller V, Babilas P, Karrer S, Landthaler M, Szeimies RM. Pityriasis rubra pilaris successfully treated with adalimumab. Clin Exp Dermatol. 2010 Oct;35(7):792-3.

Wassef C, Lombardi A, Rao BK. Adalimumab for the Treatment of Pityriasis Rubra Pilaris: A Case Reprot. Cutis. 2012 November;90(5):244-247.

Bravo E, Carrion L, Paucar, SM, Mendoza R, Rivera C. Successful treatment of pityriasis rubra pilaris with adalimumab. Dermatol Online Journal. 2014 Jan;20(4):11.

Petrof G, Almaani N, Archer C, Griffiths W, Smith C. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists. JEADV 2013; 27: 131-5. 


Kouklakis G, Efremidou E, Pitiakoudis M, et al. Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn’s disease: a case report and review of the hypothetical association between TNF-α blockers and cancer. Drug Des Devel Ther. 2013.7: 195-9